The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae

Abstract In the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant Enterobacteriaceae (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMP-SMX. Development of resistance further limits the use of TMP-SMX in CRE infections.

Primary Author

Luterbach,Courtney L.

Boshe,Ashley

Henderson,Heather I.

Cober,Eric

Richter,Sandra S.

Salata,Robert A.

Kalayjian,Robert C.

Watkins,Richard R.

Hujer,Andrea M.

Hujer,Kristine M.

Rudin,Susan D.

Domitrovic,T. Nicholas

Doi,Yohei

Kaye,Keith S.

Evans,Scott

Fowler,Vance G.

Bonomo,Robert A.

van Duin,David

Volume

Issue

Other Pages

ofy351

Publisher

Oxford University Press

URL

https://www.ncbi.nlm.nih.gov/pubmed/30631796

PMID

30631796

Reference Type

Journal Article

Periodical Full

Open forum infectious diseases

Publication Year

2019

Publication Date

Jan

Place of Publication

ISSN/ISBN

2328-8957

Document Object Index

10.1093/ofid/ofy351